698 related articles for article (PubMed ID: 28432745)
1. Safety of sitagliptin in patients with type 2 diabetes and chronic kidney disease: outcomes from TECOS.
Engel SS; Suryawanshi S; Stevens SR; Josse RG; Cornel JH; Jakuboniene N; Riefflin A; Tankova T; Wainstein J; Peterson ED; Holman RR;
Diabetes Obes Metab; 2017 Nov; 19(11):1587-1593. PubMed ID: 28432745
[TBL] [Abstract][Full Text] [Related]
2. Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.
Cornel JH; Bakris GL; Stevens SR; Alvarsson M; Bax WA; Chuang LM; Engel SS; Lopes RD; McGuire DK; Riefflin A; Rodbard HW; Sinay I; Tankova T; Wainstein J; Peterson ED; Holman RR;
Diabetes Care; 2016 Dec; 39(12):2304-2310. PubMed ID: 27742728
[TBL] [Abstract][Full Text] [Related]
3. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
Wheeler DC; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Toto RD; Sjöström CD; Langkilde AM; Heerspink HJL;
Lancet Diabetes Endocrinol; 2021 Jan; 9(1):22-31. PubMed ID: 33338413
[TBL] [Abstract][Full Text] [Related]
4. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
[TBL] [Abstract][Full Text] [Related]
5. Sitagliptin and cardiovascular outcomes in diabetic patients with chronic kidney disease and acute myocardial infarction: A nationwide cohort study.
Chen DY; Wang SH; Mao CT; Tsai ML; Lin YS; Chou CC; Wen MS; Wang CC; Hsieh IC; Hung KC; Chen TH
Int J Cardiol; 2015 Feb; 181():200-6. PubMed ID: 25528312
[TBL] [Abstract][Full Text] [Related]
6. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
McGuire DK; Van de Werf F; Armstrong PW; Standl E; Koglin J; Green JB; Bethel MA; Cornel JH; Lopes RD; Halvorsen S; Ambrosio G; Buse JB; Josse RG; Lachin JM; Pencina MJ; Garg J; Lokhnygina Y; Holman RR; Peterson ED;
JAMA Cardiol; 2016 May; 1(2):126-35. PubMed ID: 27437883
[TBL] [Abstract][Full Text] [Related]
7. [TECOS: confirmation of the cardiovascular safety of sitaliptin].
Scheen AJ; Paquot N
Rev Med Liege; 2015 Oct; 70(10):511-6. PubMed ID: 26727841
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
[TBL] [Abstract][Full Text] [Related]
9. Higher-Dose Sitagliptin and the Risk of Congestive Heart Failure in Older Adults with CKD.
Muanda FT; Weir MA; Bathini L; Clemens KK; Perkovic V; Sood MM; McArthur E; Sontrop JM; Kim RB; Garg AX
Clin J Am Soc Nephrol; 2020 Dec; 15(12):1728-1739. PubMed ID: 33239410
[TBL] [Abstract][Full Text] [Related]
10. Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial.
Perkovic V; Toto R; Cooper ME; Mann JFE; Rosenstock J; McGuire DK; Kahn SE; Marx N; Alexander JH; Zinman B; Pfarr E; Schnaidt S; Meinicke T; von Eynatten M; George JT; Johansen OE; Wanner C;
Diabetes Care; 2020 Aug; 43(8):1803-1812. PubMed ID: 32444457
[TBL] [Abstract][Full Text] [Related]
11. Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.
Nauck MA; McGuire DK; Pieper KS; Lokhnygina Y; Strandberg TE; Riefflin A; Delibasi T; Peterson ED; White HD; Scott R; Holman RR
Cardiovasc Diabetol; 2019 Sep; 18(1):116. PubMed ID: 31481069
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Barnett AH; Mithal A; Manassie J; Jones R; Rattunde H; Woerle HJ; Broedl UC;
Lancet Diabetes Endocrinol; 2014 May; 2(5):369-84. PubMed ID: 24795251
[TBL] [Abstract][Full Text] [Related]
13. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Bethel MA; Engel SS; Green JB; Huang Z; Josse RG; Kaufman KD; Standl E; Suryawanshi S; Van de Werf F; McGuire DK; Peterson ED; Holman RR;
Diabetes Care; 2017 Apr; 40(4):494-501. PubMed ID: 28057693
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular risk of sitagliptin in ischemic stroke patients with type 2 diabetes and chronic kidney disease: A nationwide cohort study.
Liang CY; Chen DY; Mao CT; Hsieh IC; Hung MJ; Wang CH; Wen MS; Cherng WJ; Chen TH
Medicine (Baltimore); 2018 Dec; 97(52):e13844. PubMed ID: 30593182
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic Safety of Sitagliptin in the TECOS Study.
Buse JB; Bethel MA; Green JB; Stevens SR; Lokhnygina Y; Aschner P; Grado CR; Tankova T; Wainstein J; Josse R; Lachin JM; Engel SS; Patel K; Peterson ED; Holman RR;
Diabetes Care; 2017 Feb; 40(2):164-170. PubMed ID: 27630212
[TBL] [Abstract][Full Text] [Related]
16. Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.
Josse RG; Majumdar SR; Zheng Y; Adler A; Bethel MA; Buse JB; Green JB; Kaufman KD; Rodbard HW; Tankova T; Westerhout CM; Peterson ED; Holman RR; Armstrong PW;
Diabetes Obes Metab; 2017 Jan; 19(1):78-86. PubMed ID: 27607571
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes mellitus and chronic kidney disease.
Yale JF; Bakris G; Cariou B; Nieto J; David-Neto E; Yue D; Wajs E; Figueroa K; Jiang J; Law G; Usiskin K; Meininger G;
Diabetes Obes Metab; 2014 Oct; 16(10):1016-27. PubMed ID: 24965700
[TBL] [Abstract][Full Text] [Related]
18. Longitudinal medical resources and costs among type 2 diabetes patients participating in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Reed SD; Li Y; Leal J; Radican L; Adler AI; Alfredsson J; Buse JB; Green JB; Kaufman KD; Riefflin A; Van de Werf F; Peterson ED; Gray AM; Holman RR;
Diabetes Obes Metab; 2018 Jul; 20(7):1732-1739. PubMed ID: 29573215
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein(a) predicts a new onset of chronic kidney disease in people with Type 2 diabetes mellitus.
Yun JS; Ahn YB; Song KH; Yoo KD; Park YM; Kim HW; Ko SH
Diabet Med; 2016 May; 33(5):639-43. PubMed ID: 26202453
[TBL] [Abstract][Full Text] [Related]
20. Impact of sex and glucose-lowering treatments on hypoglycaemic symptoms in people with type 2 diabetes and chronic kidney disease. The French Chronic Kidney Disease - Renal Epidemiology and Information Network (CKD-REIN) Study.
Balkau B; Metzger M; Andreelli F; Frimat L; Speyer E; Combe C; Laville M; Jacquelinet C; Briançon S; Ayav C; Massy Z; Pisoni RL; Stengel B; Fouque D
Diabetes Metab; 2019 Apr; 45(2):175-183. PubMed ID: 29706470
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
